About
Hakan Goker is Managing Director and head of the Biotechnology team at M Ventures, the strategic venture capital fund of Merck KGaA, where he oversees healthcare and life sciences investments. With 15 years of venture investing experience across Atlas Venture, Aescap Venture, and M Ventures since 2013, Goker has been involved in the formation and management of multiple companies including Artios Pharma, Orphazyme, f-Star, Bicycle Therapeutics, Nimbus Discovery, Storm Therapeutics, and Ribometrix. He is responsible for directing M Ventures' portfolio strategy from its Amsterdam headquarters, with additional offices in the US and Israel, focusing on early-stage investments and company creation in transformational biotechnology.
Experience
- M VenturesManaging Directorcurrent2021 — present
- M VenturesVice President, Head of Healthcare Investments2020 — 2021Amsterdam, North Holland, Netherlands
- M VenturesExecutive Investment Director2019 — 2020The Randstad, Netherlands
- M VenturesSenior Investment Director2013 — 2018
- NRG TherapeuticsBoard Observercurrent2025 — present
- TRIMTECH Therapeutics LimitedBoard Membercurrent2025 — present
- ReproNovoBoard Membercurrent2024 — present
- NouscomBoard Membercurrent2023 — present
- Artios Pharma LtdBoard Membercurrent2016 — presentGreater Cambridge Area
- iOncturaBoard Member (ex- founding chairman)current2020 — presentGeneva, Switzerland
- iOncturaChairman Of The Board2017 — 2020Switzerland
- RibometrixBoard Membercurrent2018 — presentRaleigh-Durham-Chapel Hill Area
- STORM Therapeutics LimitedBoard Membercurrent2015 — presentGreater Cambridge Area
- Asceneuron SABoard Director and previous acting CBO &Observercurrent2013 — presentLausanne, Vaud, Switzerland
- BioPartnerAdvisory Board Membercurrent2013 — present
- Anglo Nordic Biotechnology and Medtech ConferenceCommittee Chairmancurrent2008 — presentUK and Nordic Regions
- ActitheraChairman2021 — 2025Boston, Massachusetts, United States
- Forendo Pharma LtdBoard Director2014 — 2021Finland
- SynAffix BVBoard Director2013 — 2021Netherlands
- Macrophage PharmaBoard Member2017 — 2021United Kingdom
Education
- University of LondonPhD, Molecular Genetics1997 — 2000
- Association of International Cancer Research (AICR) ScholarDoctor of Philosophy (PhD)1997 — 2000
- Chevening/ Commonwealth Scholar1993 — 1996
- UCLBSc Hons, Human Genetics1993 — 1996
- The English School - North CyprusHigh School1988 — 1993
Skills & more
+12 more
Drug DiscoveryMolecular BiologyTechnology TransferClinical DevelopmentCorporate DevelopmentStart-upsenterpreneurshipBusiness StrategyPharmaceutical IndustryStrategyEntrepreneurshipR&DFrom Hakan's professional profile.
Same school
Also attended University of London82
+ 76 more
Shared employers
Also worked at M Ventures25
+ 19 more
















_edited_edited.jpg)














